Rhythm Pharmaceuticals (RYTM) Insider Mcgirr Buys 4,712 Shares

David McGirr, an insider at Rhythm Pharmaceuticals, Inc. (NasdaqGM: RYTM), purchased 4,712 shares of the company on June 23, 2026. This insider buying activity highlights continued interest in the biotechnology firm, which focuses on treating rare neuroendocrine diseases.

Insider Buying and Selling at Rhythm Pharmaceuticals, Inc.

On June 23, 2026, David McGirr bought 4,712 shares of Rhythm Pharmaceuticals. This transaction was not part of a pre-planned trading program. Other insiders, including Jennifer Good and Stuart Arbuckle, also acquired shares on June 24, 2026, further signaling confidence in the company's ongoing projects.

Other Institutional Activity in Rhythm Pharmaceuticals

Several institutional investors have adjusted their positions in Rhythm Pharmaceuticals. BlackRock, Inc. reduced its holdings by 60,183 shares, ending with about 6.24 million shares worth approximately $542.4 million. Meanwhile, Primecap Management Co/CA/ trimmed its stake by 61,160 shares, holding about 3.42 million shares valued at $297.2 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC opened new positions, each acquiring over 2.9 million shares, signaling fresh interest in the stock.

Rhythm Pharmaceuticals, Inc. Stock Up 10.1%

Shares of Rhythm Pharmaceuticals traded near $107.55 on Friday. The company has a market cap of approximately $6.95 billion. It is not currently profitable, reflected in a negative forward P/E ratio of -136.76. The stock's beta is 1.923, indicating higher volatility compared to the market. Over the past year, the stock has ranged from a low of $60.8 to a high of $122.2, with 50-day and 200-day moving averages of $88.36 and $97.77, respectively.

Analysts Set New Price Targets

Analysts continue to show strong support for Rhythm Pharmaceuticals, with firms like Canaccord Genuity and Wells Fargo maintaining "buy" ratings. Canaccord Genuity set a price target of $151 on June 16, 2026, while Wells Fargo maintained a target of $155 on June 15, 2026. The consensus among analysts is a "strong buy," with an average target price of $139.47 based on 15 opinions.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts. It specializes in developing treatments for rare neuroendocrine diseases. The company's lead product, IMCIVREE, targets conditions such as POMC and LEPR deficiency obesity. Rhythm is actively engaged in clinical trials for various indications, including hypothalamic obesity and MC4R pathway diseases. Led by CEO Dr. David P. Meeker, the company employs 414 people.

Bottom Line

Insider buying at Rhythm Pharmaceuticals suggests confidence in the company's future prospects. With a market cap of nearly $7 billion and a strong buy consensus from analysts, investors are closely watching its developments. As always, remember that insider transactions are disclosed after the fact and do not necessarily predict future stock performance.